### 2.2.1 In vitro and physico-chemical data

A literature search was performed to collect available information on physico-chemical properties of ethinylestradiol ([Table 1](#table 1)).

| **Parameter**                   | **Unit**          | **Value**        | Source                            | **Description**                                |
| :------------------------------ | ----------------- | ---------------- | --------------------------------- | ---------------------------------------------- |
| MW<sup>+</sup>                  | g/mol             | 296.4            | [DrugBank DB00977](#5-references) | Molecular weight                               |
| pK<sub>a,acid</sub><sup>+</sup> |                   | 10.33            | [DrugBank DB00977](#5-references) | Acidic dissociation constant                   |
| Solubility (pH)<sup>+</sup>     | mg/mL             | 6.77e-3<br />(7) | [DrugBank DB00977](#5-references) | Aqueous Solubility                             |
| logD                            |                   | 3.63 - 3.9       | [DrugBank DB00977](#5-references) | Distribution coefficient                       |
| fu<sup>+</sup>                  | %                 | 3                | [DrugBank DB00977](#5-references) | Fraction unbound in plasma                     |
| CYP1A2 CL<sup>+</sup>           | µl/min/pmol       | 0.51             | [Ezuruike 2018](#5-references)    | Clearance by CYP1A2                            |
| CYP2C8 CL<sup>+</sup>           | µl/min/pmol       | 0.13             | [Ezuruike 2018](#5-references)    | Clearance by CYP2C8                            |
| CYP2C9 CL<sup>+</sup>           | µl/min/pmol       | 0.51             | [Ezuruike 2018](#5-references)    | Clearance by CYP2C9                            |
| CYP3A4 CL<sup>+</sup>           | µl/min/pmol       | 0.5              | [Ezuruike 2018](#5-references)    | Clearance by CYP3A4                            |
| Km UGT1A1<sup>+</sup>           | µmol/l            | 19.22            | [Ezuruike 2018](#5-references)    | UGT1A1 saturation constant                     |
| Vmax UGT1A1<sup>+</sup>         | pmol/min/mg prot. | 408.5            | [Ezuruike 2018](#5-references)    | Maximal metabolization rate by UGT1A1          |
| Renal Elimination<sup>+</sup>   | l/h               | 2.079            | [Stanczyk 2013](#5-references)    | Renal clearance                                |
| Clint HLM<sup>+</sup>           | µL/min/mg prot.   | 118.83           | [Ezuruike 2018](#5-references)    | Inttrinsic clearance in Human Liver Microsomes |
| Ki CYP1A2                       | µmol/l            | 10.6             | [Karjalainen 2008](#5-references) | CYP1A2 inhibition constant                     |

**Table 1:**<a name="table 1"></a> Physico-chemical and *in-vitro* metabolization properties of ethinylestradiol extracted from literature. *<sup>+</sup>: Value used in final model*

### 2.2.2 Clinical data

A literature search was performed to collect available clinical data on ethinylestradiol ([Table 2](#table 2)).

| **Source**           | Route | **Dose [mg]/**  **Schedule \*** | **Pop.**     | **Sex** | **N** | **Form.** |
| -------------------- | ------------------------------- | ------------ | ------- | --------------------------------- | --------------------------------- | --------------------------------- |
| [Back 1981](#5-references)<sup>+</sup> | i.v.   | 0.03                            | HV       | F       | 5     | solution            |
| [Back 1981](#5-references)<sup>+</sup>          | p.o.  | 0.03                            | HV       | F       | 5     | tablet              |
| [Back 1979](#5-references)<sup>+</sup>          | i.v.  | 0.05                            | HV       | F       | 6     | solution            |
| [Back 1979](#5-references)<sup>+</sup>          | p.o.  | 0.05                            | HV       | F       | 6     | NA                  |
| [Back 1987](#5-references)                      | p.o.  | 0.05 q.d.                      | HV       | F       | 5     | tablet              |
| [Orme 1991](#5-references)<sup>+</sup>          | i.v.  | 0.03                            | HV       | F       | 10    | solution            |
| [Orme 1991](#5-references)<sup>+</sup>          | p.o.  | 0.03                            | HV       | F       | 10    | tablet              |
| [Kuhnz 1996](#5-references)                     | i.v.  | 0.06                            | HV       | F       | 19    | solution            |
| [Goebelsmann 1986](#5-references)<sup>+</sup>   | p.o.  | 0.03                            | HV       | F       | 24    | solution and tablet |
| [Stanczyk 1983](#5-references)<sup>+</sup>      | p.o.  | 0.12                            | HV       | F       | 24    | solution and tablet |
| [Zhang 2017](#5-references)<sup>+</sup>         | p.o.  | 0.03                            | HV       | F       | 12    | tablet              |
| [Martin 2016](#5-references)                    | p.o.  | 0.03 q.d.                       | HV       | F       | 27    | tablet              |
| [Stockis 2014](#5-references)                   | p.o.  | 0.03 q.d.                       | HV       | F       | 24    | tablet              |
| [Sidhu 2006](#5-references)                     | p.o.  | 0.03 q.d.                       | HV       | F       | 16    | tablet              |
| [Kothare 2012](#5-references)<sup>+</sup>       | p.o.  | 0.03/0.03 q.d.                  | HV       | F       | 20    | tablet              |
| [Timmer 2000](#5-references)<sup>+</sup>        | p.o.  | 0.03                            | HV       | F       | -     | tablet              |

**Table 2:**<a name="table 2"></a> Literature sources of clinical concentration data of ethinylestradiol used for model development and validation. *\*: single dose unless otherwise specified;<sup>+</sup>: Data used for final parameter identification*